Hepatitis B Exposure Risk, Prevalence in the US Adult Homeless Population
Hepatitis B virus prevalence was 7 to 10 times higher in a homeless population of Los Angeles compared to the general population of the United States.
Hepatitis B
Hepatocellular Carcinoma Prediction Beyond Year 5 of Therapy in Chronic Hepatitis B
A study identifies risk factors for hepatocellular carcinoma (HCC) after the first 5 years of receiving antiviral therapy in white patients with chronic hepatitis B.
Mother‐to‐Child Transmission Risk in Pregnant Women With Chronic HBV
Front-line providers minimally could check HBV DNA and ALT during pregnancy to assess mother‐to‐child transmission risk but HBeAg is recommended to be included in the initial HBV evaluation to get a more comprehensive understanding of the patient’s HBV disease state.
Weight Loss Normalizes ALT and Improves Long-Term Outcomes in Chronic Hepatitis B
Because after hepatitis B viral suppression the cause and intervention for elevated alanine aminotransferase is somewhat unknown, investigators conducted a real-world study.
Conflict-Driven Migration Increases Hepatitis Burden as Production Costs Fall
Researchers of studies on the effect of conflict-driven migration on rates of hepatitis indicate that mass migration from high-burden countries has significantly increased the prevalence of both hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in the host nation.
DAA Therapy Associated With Higher Survival in HCV-Related Comorbidities
Patients with hepatitis C virus (HCV) and comorbidities, including hepatocellular carcinoma (HCC), clinically significant portal hypertension, and cirrhosis were shown to have significantly higher survival rates when treatment included directly acting antiviral agent (DAA) therapy, according to the results of several studies presented at the American Association for the Study of Liver Diseases’ The Liver…
New EMR-Based Tools Improve Hepatitis Screening in Various Care Settings
New diagnostic tools used to identify hepatitis C virus (HCV) and hepatitis B virus (HBV) utilize simple questionnaires and emergency medical records (EMR) to alert physicians in both primary care and high-volume care settings about patients at risk for viral hepatitis infection or reactivation. The results of these studies were presented at the American Association…
Managing Nucleos(t)ide Analog Treatment in Patients With Chronic Hepatitis B
Pegylated-interferon (PEG-IFN) added to nucleos(t)ide analog (NA) treatment may be associated with hepatitis B surface antigen (HbsAg) decline and once HbsAg-seroclearance is achieved, discontinuation of NA is not associated with a higher risk for HbsAg-reversion.
Hepatitis B Vaccine Responses and Best Practices
Data from 4 studies presented at The American Association for the Study of Liver Diseases’ The Liver Meeting 2019, held November 8 to 12 in Boston, Massachusetts, report on safety, effectiveness, and best practice approaches in patients with chronic hepatitis B, including non- and low-responders and obese patients.
Switching TDF to TAF in Chronic Hepatitis B Is Effective, Improves Bone, Renal, and Kidney Function
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF) is safe and effective in patients with chronic hepatitis B (HBV) and was linked to improvements in bone, renal, and kidney function.
Next post in Hepatitis
